Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Arcutis Biotherapeutics Inc (Arcutis) is a biopharmaceutical company. It develops small molecules for the treatment of immune-mediated dermatological diseases and conditions. Its pipeline products include a topical roflumilast cream (ARQ-151), ARQ-252, a small molecule inhibitor of Janus kinase type 1 (JAK1) to treat rheumatoid arthritis, psoriasis, Crohn’s disease and atopic dermatitis; topical roflumilast foam (ARQ-154) targets scalp and body psoriasis and seborrheic dermatitis; ARQ-255 for inflammation in alopecia areata. Arcutis's other pipeline includes ARQ-234 for atopic dermatitis. The company also investigating novel inflammation and immunology diseases. Arcutis is headquartered in Westlake Village, California, the US.
Headquarters
United States of America
Address
3027 Townsgate Road, Suite 300, Westlake Village, California, 91361
Website
arcutis.com
Telephone
1 805 4185006
No of Employees
342
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ARQT (NASD)
Revenue (2024)
$196.5M
229.7%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
46.6%
(2024 vs 2023)
Market Cap*
$2.6B
Net Profit Margin (2024)
XYZ
83.8%
(2024 vs 2023)
* As of and is in US$
Arcutis Biotherapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | ZORYVE |
| Topical Roflumilast Cream (ARQ-151): | |
| Plaque Psoriasis and Atopic Dermatitis | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In October, the company received approval from the US Food and Drug Administration for ZORYVE (roflumilast) cream 0.05% for the treatment of mild to moderate atopic dermatitis in children 2 to 5 years of age. |
| 2025 | New Products/Services | In October, the company unveiled ZORYVE (roflumilast) cream 0.05% for the treatment of mild to moderate atopic dermatitis in children ages 2 to 5 years in the US. |
| 2024 | Regulatory Approval | In October, Arcutis Canada, Inc. received approval from Health Canada for ZORYVE (roflumilast) topical foam 0.3% to treat seborrheic dermatitis in patients 9 years of age and older. |
Competitor Comparison
| Key Parameters | Arcutis Biotherapeutics Inc | AbbVie Inc | ADC Therapeutics SA | Kura Oncology Inc | Biofrontera Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Switzerland | United States of America | United States of America |
| City | Westlake Village | North Chicago | Epalinges | San Diego | Woburn |
| State/Province | California | Illinois | - | California | Massachusetts |
| No. of Employees | 342 | 57,000 | 263 | 260 | 92 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Patrick J. Heron | Chairman | Executive Board | 2019 | 54 |
| Todd Franklin Watanabe | President; Chief Executive Officer | Senior Management | 2017 | 58 |
| Latha Vairavan | Chief Financial Officer | Senior Management | 2025 | - |
| Bethany Dudek | Chief Technology Officer | Senior Management | - | - |
| Mas Matsuda | Chief Legal Officer; Company Secretary; Executive Vice President | Senior Management | 2026 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer